1. Cell Cycle/DNA Damage
    Anti-infection
    Autophagy
  2. DNA/RNA Synthesis
    Fungal
    Autophagy

Cycloheximide (Synonyms: Naramycin A; Actidione)

Cat. No.: HY-12320 Purity: 99.17%
Data Sheet SDS Handling Instructions

Cycloheximide is an inhibitor of protein biosynthesis in eukaryotic organisms, with IC50 of 532.5 nM and 2880 nM for protein synthesis and RNA synthesis in vivo, respectively.

For research use only. We do not sell to patients.
Cycloheximide Chemical Structure

Cycloheximide Chemical Structure

CAS No. : 66-81-9

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $55 In-stock
200 mg $50 In-stock
500 mg $70 In-stock
1 g $80 In-stock
5 g $150 In-stock
10 g   Get quote  
50 g   Get quote  

* Please select Quantity before adding items.

Customer Review

    Cycloheximide purchased from MCE. Usage Cited in: Biochim Biophys Acta. 2016 Dec;1859(12):1527-1537.

    RVX208 increases CTGF and CYR61 expression and TAZ protein level in HCT116 cells.

    Cycloheximide purchased from MCE. Usage Cited in: Biochim Biophys Acta. 2016 Dec;1859(12):1527-1537.

    JQ1 treatment decreases β-catenin levels in HCT116 cells, but increases TAZ protein. When cells reach confluence, they are serum-starved overnight and pretreated with DMSO or JQ1 (500 nM) for 1 hour, followed by growth medium (containing 10% serum) stimulation for 24 hours.

    Cycloheximide purchased from MCE. Usage Cited in: Oncotarget. 2016 May 10;7(19):27176-84.

    PIG3 silencing does not affect the degradation of HIF-1α protein under hypoxia. Forty-eight hours after transfection with PIG3-siRNA or negative control siRNA, CAKI cells are pretreated under hypoxia for 4 h followed by treatment with 100 μg/mL Cycloheximide (CHX) to block protein synthesis for the indicated times. The mean values from two experiments are connected by the lines. Protein levels are analyzed by Immunoblotting, GAPDH is employed a loading control. All the experiments above are cond

    Cycloheximide purchased from MCE. Usage Cited in: Biochem Biophys Res Commun. 2017 Sep 2;490(4):1168-1175.

    SR-B1 protein is degraded by proteasome pathway. (A) SR-B1 is degraded in a CHX dose-dependent manner in CHO-K1 cells. (B) Time course of SR-B1 degradation in CHO-K1 cells treated with CHX.

    Cycloheximide purchased from MCE. Usage Cited in: Biochem Biophys Res Commun. 2017 Sep 2;490(4):1168-1175.

    Treatment of CHO-K1 cells with proteasome inhibitor, MG-132 results in elevated SR-B1 protein levels. The cells with MG-132, a potent proteasome inhibitor that inhibit ubiquitin/proteasome-dependent protein degradation, and MG-132 treatment significantly enhances cellular SR-B1 protein level.

    Cycloheximide purchased from MCE. Usage Cited in: Cell Death Dis. 2017 Sep 14;8(9):e3048.

    Cells are treated with CHX in the presence or absence of CQ and results show that the decrease NDRG1 observed after CHX treatment is partially recovered upon co-treatment with CHX and CQ.
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References

    Description

    Cycloheximide is an inhibitor of protein biosynthesis in eukaryotic organisms, with IC50 of 532.5 nM and 2880 nM for protein synthesis and RNA synthesis in vivo, respectively.

    IC50 & Target

    IC50: 532.5 nM (protein synthesis), 2.88 μM (RNA synthesis)[1]

    In Vitro

    Cycloheximide (CHX) is the most common laboratory reagent used to inhibit protein synthesis. Cycloheximide has been shown to block the elongation phase of eukaryotic translation. Cycloheximide binds the ribosome and inhibits eEF2-mediated translocation. Surprisingly, Cycloheximide allows one complete translocation cycle to proceed before halting any further elongation. Cycloheximide has been speculated that Cycloheximide requires an E-site bound deacylated tRNA for activity[1].

    In Vivo

    The mice receive Cycloheximide injections at 30, 60, or 120 mg/kg prior to training with a 200 µA shock. There is a significant effect of Cycloheximide on latencies on the memory test trials (P<0.001). In saline controls, this shock level results in latencies on the test trial that are significantly higher than those at training. Injections of the lowest dose of Cycloheximide tested, 30 mg/kg, results in latencies on the test trial that are significantly higher than those seen in the saline control group. Mice receiving either of the two higher doses of Cycloheximide has latencies on the test trial that are comparable to those of the saline group, i.e., the higher doses neither enhanced nor impaired memory under these conditions, resulting in an inverted-U dose-response curve for Cycloheximide enhancement of memory[2]. Infarct volume, as measured by morphometric analysis of infarct areas with triphenyl tetrazolium chloride (TTC), is significantly reduced by 92% and 61% when Cycloheximide is given 0 or 6 hr after HI respectively, but shows an insignificant trend in infarct reduction if Cycloheximide is administered 12 hr after hypoxia-ischemia (HI) compared to the HI control group, and no protective effect is observed when administration is delayed until 24 hr after HI[3].

    References
    Preparing Stock Solutions
    Concentration Volume Mass 1 mg 5 mg 10 mg
    1 mM 3.5543 mL 17.7715 mL 35.5429 mL
    5 mM 0.7109 mL 3.5543 mL 7.1086 mL
    10 mM 0.3554 mL 1.7771 mL 3.5543 mL
    Please refer to the solubility information to select the appropriate solvent.
    Cell Assay
    [1]

    Cycloheximide is dissolved in stock solutions, and then serially diluted with appropriate media before use[1].

    To test cell proliferation, 3000-5000 cells (HeLa, HTB1 and HEK 293T cells; Jurkat, BT 474, HCC 1395, HCC 1937, HCC 2218 and MDA MB231 cells; MCF 10A) per well are plated in a 96-well plate and allowed to adhere overnight. Cycloheximide dissolved in DMSO at the indicated concentrations (0.1 nM-1000μM) are then added and cells are incubated for a further 24 h. [3H]-thymidine is added at 1 μCi per well and incubation is continued for an additional 7 h. Cells are washed twice with PBS and then trypsinized before they are collected with a Tomtec harvester and bound to GF/C filter mats. Thymidine uptake is then measured by scintillation counting[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [2][3]

    Cycloheximide (CHX) is dissolved in saline (Mice)[2].

    Mice[2]
    Male ICR mice (approximately 2 months old) are used in this experiment. Cycloheximide is administered IP at concentrations of 0 (saline controls), 30, 60, or 120 mg/kg. Cycloheximide injections are administered 30 min prior to training. The 120 mg/kg dose is commonly used to study amnesia in mice. Note that amnestic Cycloheximide doses are much lower in rats (1-3 mg/kg) than in mice, consistent with a similar difference in LD50s for rats and mice. Cycloheximide doses of 120-150 mg/kg result in approximately 95% inhibition of brain protein synthesis as measured 30-60 min after injection; the dose of 30 mg/kg produces approximately 80% inhibition of brain protein synthesis.
    Rat[3]
    Unilateral carotid artery ligation is performed in 7-day old Sprague Dawley rat pups under methoxyflurane anesthesia. The neck is incised in the midline, and the right common carotid artery is permanently ligated with 4-0 silk. Total time of surgery in each animal never exceeded 5 min. Following surgery, rats are returned to their mother for recovery and feeding for 2 hr. The pups are then exposed to a 100 min-period of hypoxia (8% O2, 92% N2) by placing them in an airtight chamber partially submerged in a temperature controlled water bath to maintain the ambient temperature inside the chamber at a constant 36℃. In the HI with Cycloheximide treatment group, the rat pups receive an intraperitoneal injection of Cycloheximide at a dose of 0.6 mg/kg at 0, 6, 12 or 24 hr of recovery, and an equal volume of normal saline is given to a HI control group. Then, the rat pups are returned to their dam until sacrifice; the whole brain tissue is obtained under deep pentobarbital anesthesia (60 mg/kg, intraperitoneal) for flow cytometry and triphenyl tetrazolium chloride (TTC) at 48 and 72 hr after HI, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References
    Molecular Weight

    281.35

    Formula

    C₁₅H₂₃NO₄

    CAS No.

    66-81-9

    Storage
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Shipping

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    DMSO: ≥ 33 mg/mL; H2O: 20 mg/mL (Need ultrasonic and warming)

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    Purity: 99.17%

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number

     

    Organization name *

    Country *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Cycloheximide
    Cat. No.:
    HY-12320
    Quantity: